Do you have to keep increasing semaglutide — or can you stay at one dose?

Step 1, starting low: why the dose begins at 0.25mg

Semaglutide's dose escalation schedule is designed around one priority: keeping side effects manageable while your body adapts. The starting dose (0.25mg weekly for the first four weeks) is not intended to produce significant weight loss. Its job is to settle your digestive system before the therapeutic dose is introduced. Think of it as a run-in period rather than treatment proper.

From there, the schedule moves upward roughly every four weeks: 0.25mg to 0.5mg, then 1mg, 1.7mg, and finally 2.4mg as the standard maintenance dose. The higher dose approved more recently (7.2mg) follows the same gradual principle, with titration guided by your prescriber throughout. You can read more about how semaglutide works as a medicine on the semaglutide overview page. The NHS also explains the full titration pathway on its semaglutide medicines page.

The key point is that this is a schedule your prescriber follows with you, not a conveyor belt you cannot step off. Each increase is a clinical decision, not an automatic step.

Step 2, the prescriber's review: when staying at one dose makes sense

A question our prescribers hear most weeks is some version of: "do I have to go higher if things are going well?" The answer is that the clinical goal is the lowest effective dose, not the highest tolerated one. If you are losing weight steadily, not experiencing troublesome side effects, and feeling well at, say, 1mg or 1.7mg, there is no clinical requirement to push to 2.4mg.

NICE guidance on semaglutide notes that treatment should be reviewed if less than 5% weight loss is achieved after six months at the maintenance dose, which implies that reaching a dose plateau earlier, with good results, is the normal successful outcome rather than an exception. You can find more detail on what happens to the dose over time on the semaglutide dose-increase page.

There is also a practical dimension to this. Side effects (nausea, loose stools, fatigue) often peak after a dose increase and settle within a couple of weeks. If a particular step causes persistent discomfort, your prescriber may slow the escalation or hold you at the previous dose for longer before moving up. That flexibility is built into the schedule by design.

Step 3, long-term maintenance: what happens once you reach your target dose

Once you and your prescriber agree on the dose that suits you, the focus shifts from titration to maintenance. Semaglutide is a medicine most people take on a continuing basis while they are in the treatment programme; the question of whether to keep taking it at all is separate from whether to keep increasing it. The two questions are easily confused, and it is worth separating them clearly.

Continuing at a stable dose is straightforward week to week. The medicine is taken once weekly (the frequency page covers the practical details) and your prescriber reviews your progress before every repeat, which is standard practice at a regulated pharmacy. Some people also ask whether they need to stay on Wegovy long term; that is a different and equally fair question, and the Wegovy long-term use page addresses it directly.

One thing worth knowing: if you stop semaglutide and then restart, the titration schedule typically begins again from the lowest dose, and if you have noticed changes to your sleep patterns during treatment, our page on whether Wegovy keeps you awake covers what the evidence says. Your prescriber will advise based on how long you were off treatment and how your body responded before.

Practical considerations for your dose conversation

Because semaglutide is a prescription-only medicine, the dose you take is ultimately the one a clinician approves for you, not the one you find referenced online or one a friend is taking. Context matters: your starting weight, any existing health conditions, how you are responding, and what results you are seeing all shape the decision.

If you are unsure about the costs involved in private treatment, the Wegovy pricing page sets out what to expect in plain terms. For a broader look at your treatment options, the weight-loss treatments overview explains what is currently licensed in the UK. The NICE appraisal of semaglutide (TA875) is also publicly available if you want to read the clinical evidence behind the recommendations.

If you have questions specific to your situation (whether to increase, when to hold, or what the next step looks like) speaking to a prescriber is the right move. At nume, a real clinician reads your consultation the same day and can give you answers grounded in your actual picture, not a generic schedule. Speak to our prescribers when you are ready.